Entheon Biomedical Corp. · CSE:ENBI.X

Entheon Biomedical — Investor Presentation (March 2021)

36 slides from Entheon Biomedical's investor presentation, March 2021

Slide 1: A New Dimension in Addiction Treatment
1 A New Dimension in Addiction Treatment
Slide 2: A Staggering Crisis
A STAGGERING CRISIS “The estimated cost of drug abuse in the United States—including illegal drugs, alcohol, and tobacco—is more than $740 billion a year and growing…” -National Institute on Drug Abuse © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED
Slide 4: The Global Addiction Dilemma
THE GLOBAL ADDICTION DILEMMA >2% of the global population has an alcohol or illicit drug addiction 11.4M tobacco and illicit drug-use Die prematurely from alcohol, © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED
Slide 5: Significant Unmet Need
SIGNIFICANT UNMET NEED “21.2 million Americans have a substance use disorder. In 2018, just 11% of those patients received the treatment they needed.” Association of American Medical Colleges © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED
Slide 6: Addiction: The Epidemic of Our Times
The Situation 6 Addiction: Alcohol(US) Opioids(US) Smoking(US) The Epidemic of Our Times Deaths The current treatment model is not equipped to handle an exponentially growing crisis Instances Receive Treatment Annual Economic Impact © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED
Slide 8: Substance-Use is a Complex Disorder
The Situation 8 Substance-Use is a Complex Disorder + Complicated diagnosis, developed over time + Removal of substance does not guarantee abstinence + The root is thought to be psychological and emotional in nature, rather than purely habitual + Solutions must be targeted at psychological and emoti
Slide 10: Inverting the Expectations
10 INVERTING THE EXPECTATIONS When it comes to treating addiction, the rate of success is so low that society has been conditioned to accept – and even expect - failure. Focusing primarily on the powerful DMT molecule and its therapeutic potential, Entheon exists to invert the addiction recovery rat
Slide 12: What is DMT?
WHAT IS DMT? DMT is one of the classic psychedelics, along with mescaline, LSD, and psilocybin. All are serotonin 5-HT2A receptor agonists (serotonergic hallucinogens) and share similar effects. DMT is the Most Powerful of the Classic Psychedelics Used therapeutically for Scientifically studied Pres
Slide 13: DMT
The Molecule 13 DMT The Psychedelic Experience Perspectives & possibilities Although the DMT state is highly subjective ▪ Dismantles deeply held beliefs many experiencers report common phenomenon ▪ Provides breakthrough clarity ▪ Unusually vivid visual imagery and somatic effects ▪ Gravitational pul
Slide 14: DMT disrupts the Default Mode Network
The Molecule 14 DMT disrupts the Default Mode Network (DMN) DMN The way our brain responds to stimuli based on ingrained patterns ▪ Beliefs ▪ Values ▪ Ethics ▪ Reactions ▪ Habits © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED
Slide 15: DMT brain activity
The Molecule DMT Standard Brain Activity DMT Brain N,N-Dimethyltryptamine (DMT) Activity an introspective psychedelic compound © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED
Slide 16: Limitations of Other Molecules & Compounds
The Molecule 16 Limitations of Other Molecules & Compounds Ayahuasca, Psilocybin & LSD DMT + Long duration (6-8hrs) + Shorter session length + Difficult to scale + Higher patient throughput & access + Limited means of ending a + Ability to end session if too intense negative adverse reaction + Titra
Slide 18: Entheon's DMT Protocol
The Entheon Treatment Entheon’s DMT Protocol Continuous IV Infusion of DMT [1C o n t ext And intent ] [2 DMT i n f u si on ] [3 ] I n t e gra ti o n + Trust + 60-90 minutes + Strengthen New Perspectives Administered Within + Beliefs + Physician a Medical Context Assisted + Ongoing Support + Trauma +
Slide 19: Indications
INDICATIONS Initial Target Indications Potential Indications Nicotine cessation Behavioural addictions (e.g.food,gambling,sex) Opioid-use disorder Alcoholism Additional mental health indications © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED
Slide 20: Estimated Clinical Trial Timeline
Research & Development 20 Estimated Clinical Trial Timeline Proof of Concept Human Study (Phase 1/2a equivalent) Alcohol and Opiate Addiction Pilot Studies (Phase 1/2a) Nicotine Addiction Multicenter Study (Phase 2b/3) Pre-clinical In Vivo DMT Study Nicotine Addiction Pilot Study in US (Phase 1/2a)
Slide 22: The Psychedelic patient journey is not an isolated event
The Entheon Treatment 22 The Psychedelic patient journey is not an isolated event Entheon is developing tools to support all stages of the patient’s journey. Increased safety Precision dosing Personalized Therapies © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED © ENTHEON HOLDINGS CORP. 2020 | A
Slide 23: A Patient-centric & Personalized System of Psychedelic Medicine
The Situation 23 A Patient-centric & Personalized System of Psychedelic Medicine + Preparation > + Intra Experience > + Post-therapy ▪ ▪ © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED
Slide 24: The Entheon Intelligence Platform
THE ENTHEON INTELLIGENCE PLATFORM A highly individualized diagnostic patient-monitoring system that ventures to enhance safety and optimize the outcomes at all stages of the patient journey. © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED
Slide 26: HaluGen Life Sciences Inc. Acquisition
Partnership, Acquisition, and Investment Strategy 26 HaluGen Life Sciences Inc. Acquisition Key genotypes + HTR2A – sensitivity to serotonergic psychedelics Developing and commercializing a pre-screening test to identify genetic markers. + CYP2B6- ketamine metabolic + Predict an individual's reactio
Slide 27: Partnership with Divergence Neuro Inc.
Partnership, Acquisition, and Investment Strategy 27 Partnership with Divergence Neuro Inc. + Designed to inform, modify, and optimize psychedelic-assisted therapy + Development of drug specific & phenotype biomarkers + Track changes over time © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED
Slide 28: Investment into Heading Health, LLC
Partnership, Acquisition, and Investment Strategy 28 Investment into Heading Health, LLC + Provides exposure to US-based ketamine-assisted therapy space and Heading’s full-suite of therapies and diagnostic tools for the treatment of mental health disorders, including the fully regulated and insurabl
Slide 30: Our Team
Our Team 30 Timothy Ko Andrew Hegle Ph.D., M.Sc. Brian Jahns, PharmD Brandon Schwabe CPA, CGA CHIEF EXECUTIVE OFFICER DIRECTOR OF OPERATIONS, CSO CHIEF BUSINESS OFFICER CHIEF FINANCIAL OFFICER Broad background of leading Adjunct professor of 20+ years of A decade of professional private ventures in
Slide 31: Our Team
Our Team 31 Yaron Eshel Christopher Gondi Ph.D., M.Sc. Ruth Chun M.A., J.D. Nancy Maher PROJECT MANAGER BOARD MEMBER BOARD MEMBER SPECIAL ADVISOR Has led clinical trials and Depts. Of Medicine, Surgery and Corporate commercial Technology & pharma worked with CRO’s all over Pathology at the Universit
Slide 32: Scientific Advisory Board
Scientific Advisory Board 32 Matthew W. Johnson Robin-Carhart Harris Dennis McKenna Christopher Timmerman Ph.D., M.Sc. Ph.D. Ph.D. Ph.D. Professor of Psychiatry and Head, The Psychedelic Research Ethno-pharmacologist, research, Lead Researcher, The Psychedelic pharmacognosist, lecturer and author Re
Slide 34: The Opportunity
THE OPPORTUNITY “The psychedelic drugs market is projected to grow at a CAGR of 16.3% over the next eight years to reach $6.85 billion by 2027.” © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED
Slide 35: Financials
Financials 35 Nov. 12, 2020 Commenced trading on the CSE CSE: ENBI Outstanding Shares 54,038,933 FSE: 1XU1 Fully diluted 67,569,604 OTC: ENTBF Current Cash Position 4.7 M CAD © ENTHEON HOLDINGS CORP. 2020 | ALL RIGHTS RESERVED
Slide 36: Thank You
Thank You | entheonbiomedical.com | info@entheonbiomedical.com

Entheon Biomedical — Investor Presentation (March 2021) on 6ix

Entheon Biomedical — Investor Presentation (March 2021)

Slide 1: A New Dimension in Addiction Treatment

Slide 2: A Staggering Crisis

Slide 3: The Situation

Slide 4: The Global Addiction Dilemma

Slide 5: Significant Unmet Need

Slide 6: Addiction: The Epidemic of Our Times

Slide 7: Current Treatments Lack Efficacy

Slide 8: Substance-Use is a Complex Disorder

Slide 9: Why Entheon?

Slide 10: Inverting the Expectations

Slide 11: The Molecule

Slide 12: What is DMT?

Slide 13: DMT

Slide 14: DMT disrupts the Default Mode Network

Slide 15: DMT brain activity

Slide 16: Limitations of Other Molecules & Compounds

Slide 17: The Entheon Treatment

Slide 18: Entheon's DMT Protocol

Slide 19: Indications

Slide 20: Estimated Clinical Trial Timeline

Slide 21: Research & Development

Slide 22: The Psychedelic patient journey is not an isolated event

Slide 23: A Patient-centric & Personalized System of Psychedelic Medicine

Slide 24: The Entheon Intelligence Platform

Slide 25: Partnership, Acquisition & Investment Strategy

Slide 26: HaluGen Life Sciences Inc. Acquisition

Slide 27: Partnership with Divergence Neuro Inc.

Slide 28: Investment into Heading Health, LLC

Slide 29: The Team

Slide 30: Our Team

Slide 31: Our Team

Slide 32: Scientific Advisory Board

Slide 33: Financials

Slide 34: The Opportunity

Slide 35: Financials

Slide 36: Thank You